Skip to main content
. 2012 Aug 3;4:395–404. doi: 10.2147/IJWH.S29467

Figure 1.

Figure 1

Schematic of mode of action for VEGF signaling and bevacizumab. (A) Free unbound VEGF interacting with the receptor. (B) The monoclonal antibody, bevacizumab, binds to VEGF-A, preventing ligand-receptor interaction and downstream signaling.

Abbreviation: VEGF, vascular endothelial growth factor.